Sanofi Is sponsoring a multi-center, hospital based, cross-sectional study based on data from patient medical records, including laboratory results. The study will include adult patients with chronic (> 1 year duration) primary immune thrombocytopenia (ITP) only. Patients will be identified based on a laboratory confirmed diagnosis of ITP from medical records, where there is also a physician-confirmed diagnosis of primary ITP. If patients consent to take part in the study, a routine clinical visit will also serve as the study visit. All study participants will have a routine blood test as part of their standard clinical care at the study visit, and this same procedure will be used to collect supplementary blood samples to assess a variety of biomarkers.
Participants will be excluding from participating if they have secondary ITP, or an inherited platelet disorder. ITP patients in remission for one year will also be excluded, in addition to those who have received a recent vaccination or recently received a new ITP treatment called rilzabrutinib before the index date of the study.
USA and UK
Actively Recruiting